Pharma BD Deal Intelligence
Cephalon will acquire Salt Lake City's Anesta for $444 million in stock, valuing each Anesta share at $31.45; Anesta shares jumped $10.50, or 47.5 percent, on…
The board of directors of Anesta Corp. has unanimously approved a merger with Cephalon, Inc... holders of Anesta common stock will receive 0.4765 of a share of…
Anesta shareholders approved the all-stock merger at 0.4765 Cephalon shares per Anesta share; Salt Lake City headcount to contract from 77 to ~55-60 by…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Cephalon acquired Anesta in an all-share deal worth ~$444M ($31.45/share). Brought worldwide rights to Actiq (OTFC fentanyl) for breakthrough cancer pain — Cephalon's first marketed in-house product alongside Provigil. Closed October 2000.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cephalon Inc. / Anesta Corp. (this deal) | 2000 | $444M | 64 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
| Cephalon Inc. / Cell Therapeutics, Inc. | 2005 | $70M | 74 |
| Cephalon Inc. / Anesta Corp. | 2001 | $444M | 65 |
| Cephalon Inc. / Zeneus Holdings Limited (Zeneus Pharma) | 2005 | $360M | 63 |
← Browse all deals · How we score deals
More: 2000 deals · Cephalon Inc. deals · Oncology deals